Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease. The Rotterdam Study

Neurobiology of Aging

Volumn 29, Issue 6, 2008, Pages 874-881

  Reitz, Christiane ^a   van Rooij, Frank J A ^a   de Maat, Moniek P M ^a   Heijer, Tom den ^a   Hofman, Albert ^a   Witteman, Jacqueline C M ^a   Breteler, Monique M B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Dementia; Haplotypes; Hippocampus; Matrix metalloproteinase 3; Polymorphism; White matter lesions

Indexed keywords

APOLIPOPROTEIN E; STROMELYSIN;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; DEMENTIA; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COMORBIDITY; DEMENTIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NETHERLANDS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 42649083010     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.01.001     Document Type: Article

References (42)

1. Asahina M., Yoshiyama Y., and Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 20 March (2) (2001) 60-63
2. Backstrom J.R., Lim G.P., Cullen M.J., and Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 16 December (24) (1996) 7910-7919
3. Beyzade S., Zhang S., Wong Y.K., Day I.N., Eriksson P., and Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J. Am. Coll. Cardiol. 41 June (12) (2003) 2130-2137
4. Bignami A., LeBlanc A., and Perides G. A role for extracellular matrix degradation and matrix metalloproteinases in senile dementia?. Acta Neuropathol. (Berl) 87 3 (1994) 308-312
5. Breteler M.M. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N.Y. Acad. Sci. 903 (2000) 457-465
6. Copeland J.R., Kelleher M.J., Kellett J.M., Gourlay A.J., Gurland B.J., Fleiss J.L., and Sharpe L. A semi-structured clinical interview for the assessment of diagnosis and mental state in the elderly: the Geriatric Mental State Schedule. I. Development and reliability. Psychol. Med. 6 3 (1976) 439-449
7. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell Jr. P.C., Rimmler J.B., Locke P.A., Conneally P.M., and Schmader K.E. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7 June (2) (1994) 180-184
8. Cuenod C.A., Denys A., Michot J.L., Jehenson P., Forette F., Kaplan D., Syrota A., and Boller F. Amygdala atrophy in Alzheimer's disease. An in vivo magnetic resonance imaging study. Arch. Neurol. 50 September (9) (1993) 941-945
9. Davey S.G., and Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 32 February (1) (2003) 1-22
10. den Heijer T., Vermeer S.E., Clarke R., Oudkerk M., Koudstaal P.J., Hofman A., and Breteler M.M.B. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126 January (Pt 1) (2003) 170-175
11. Diagnostic and Statistical Manual of Mental Disorders. Revised Third Edition. Washington DC, American Psychiatric Association, 1987.
12. Epstein M.P., and Satten G.A. Inference on haplotype effects in case-control studies using unphased genotype data. Am. J. Hum. Genet. 73 (2003) 1316-1329
13. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 3 (1975) 189-198
14. Hartmann D. Functional roles of APP secretases. In: Saido T.C. (Ed). Aβ Metabolism and Alzheimer's Disease (2003), Landes Bioscience, Georgetown 49-60
15. Helbecque N., Cottel D., Hermant X., and Amouyel P. Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiol. Aging July (2006) 3
16. Helbecque N., Hermant X., Cottel D., and Amouyel P. The role of matrix metalloproteinase-9 in dementia. Neurosci. Lett. 350 October (3) (2003) 181-183
17. Hofman A., Grobbee D.E., de Jong P.T., and van den Ouweland F.A. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol. 7 July (4) (1991) 403-422
18. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., and Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 January (9046) (1997) 151-154
19. Ishiura, S., Asai, M., Hattori, C., Hotoda, N., Szabo, B., Sasagawa, N., Tanuma, S. APP a-secretase, a novel target for Alzheimer drug therapy. In: Saido, T.C. (Ed.), Aβ Metabolism and Alzheimer's Disease Austin: Landes Bioscience; 2003.
20. Kardys I., de Maat M.P., Uitterlinden A.G., Hofman A., and Witteman J.C. C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur. Heart J. 27 June (11) (2006) 1331-1337
21. Kehoe P., Wavrant-De V.F., Crook R., Wu W.S., Holmans P., Fenton I., Spurlock G., Norton N., Williams H., Williams N., Lovestone S., Perez-Tur J., Hutton M., Chartier-Harlin M.C., Shears S., Roehl K., Booth J., Van Voorst W., Ramic D., Williams J., Goate A., Hardy J., and Owen M.J. A full genome scan for late onset Alzheimer's disease. Hum. Mol. Genet. 8 February (2) (1999) 237-245
22. Lake S.L., Lyon H., Tantisira K., Silverman E.K., Weiss S.T., Laird N.M., and Schaid D.J. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum. Hered. 55 (2003) 56-65
23. Lee J.M., Yin K., Hsin I., Chen S., Fryer J.D., Holtzman D.M., Hsu C.Y., and Xu J. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J. Neurol. Sci. 229-230 March (2005) 249-254
24. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
25. Newman A.B., Fitzpatrick A.L., Lopez O., Jackson S., Lyketsos C., Jagust W., Ives D., Dekosky S.T., and Kuller L.H. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc. 53 July (7) (2005) 1101-1107
26. Ott A., Breteler M.M., van Harskamp F., Stijnen T., and Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am. J. Epidemiol. 147 6 (1998) 574-580
27. Perides G., Rahemtulla F., Lane W.S., Asher R.A., and Bignami A. Isolation of a large aggregating proteoglycan from human brain. J. Biol. Chem. 267 November (33) (1992) 23883-23887
28. Pollanen P.J., Lehtimaki T., Ilveskoski E., Mikkelsson J., Kajander O.A., Laippala P., Perola M., Goebeler S., Penttila A., Mattila K.M., Syrjakoski K., Koivula T., Nikkari S.T., and Karhunen P.J. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis 164 October (2) (2002) 329-335
29. Pollanen P.J., Lehtimaki T., Mikkelsson J., Ilveskoski E., Kunnas T., Perola M., Penttila A., Mattila K.M., Nikkari S.T., Syrjakoski K., and Karhunen P.J. Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis 180 May (1) (2005) 73-78
30. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., and Goddard R. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br. J. Psychiatry 149 (1986) 698-709
31. Saido T.C., and Iwata N. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 54 April (4) (2006) 235-253
32. Samnegard A., Silveira A., Lundman P., Boquist S., Odeberg J., Hulthe J., McPheat W., Tornvall P., Bergstrand L., Ericsson C.G., Hamsten A., and Eriksson P. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J. Intern. Med. 258 November (5) (2005) 411-419
33. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70 (2002) 425-434
34. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 October (2) (2001) 177-180
35. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., and Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 September (6393) (1992) 325-327
36. Shibata N., Ohnuma T., Higashi S., Usui C., Ohkubo T., Kitajima A., Ueki A., Nagao M., and Arai H. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer's disease. Neurobiol. Aging 26 July (7) (2005) 1011-1014
37. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., and Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 October (5079) (1992) 126-129
38. Slooter A.J., Cruts M., Kalmijn S., Hofman A., Breteler M.M., Van Broeckhoven C., and van Duijn C.M. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch. Neurol. 55 7 (1998) 964-968
39. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., and Breteler M.M.B. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348 March (13) (2003) 1215-1222
40. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., and Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281 June (26) (2006) 17670-17680
41. Yoshiyama Y., Asahina M., and Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol. (Berl) 99 February (2) (2000) 91-95
42. Yoshiyama Y., Sato H., Seiki M., Shinagawa A., Takahashi M., and Yamada T. Expression of the membrane-type 3 matrix metalloproteinase (MT3-MMP) in human brain tissues. Acta Neuropathol. (Berl) 96 October (4) (1998) 347-350